⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,694.63
+0.46%
Nasdaq 100
29,549.62
+1.24%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,966.09
−0.27%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.45
+1.55%
NYSE:TSM
$421.49
+2.15%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 299.47
+0.12%
Gold
$4,145.85
−0.47%
Brent
$110.27
+0.42%
BTC
$81,942.85
−0.09%
ETH
$2,400.75
−0.27%
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,694.63
+0.46%
Nasdaq 100
29,549.62
+1.24%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,966.09
−0.27%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.45
+1.55%
NYSE:TSM
$421.49
+2.15%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 299.47
+0.12%
Gold
$4,145.85
−0.47%
Brent
$110.27
+0.42%
BTC
$81,942.85
−0.09%
ETH
$2,400.75
−0.27%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Open
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NAS
› NTRA
N
Natera Inc
NAS:NTRA
Healthcare
NASDAQ:NQUSLG
STOXX:EDD24BP
$401.58
+2.07%
Live
In session · ≈
AED 1,474.80
· Market cap
$57.89B
· Next earnings
Thu 5 Nov
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
Natera Inc · News · TradingHolo
NTRA news
Headlines tagged to this company
BU
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
BusinessWire · 4 d ago
DO
Natera Price Target Raised to $460.00/Share From $360.00 by JP Morgan
Dow Jones Newswires · 5 d ago
DO
Natera Is Maintained at Overweight by Morgan Stanley
Dow Jones Newswires · 6 d ago
DO
Natera Is Maintained at Buy by TD Cowen
Dow Jones Newswires · 6 d ago
BU
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
BusinessWire · 6 d ago
TR
Natera, Inc. (NTRA) Partners to Enroll MRD+ CRC in Phase 2a Trial
TradingView · 6 d ago
TR
Natera, Inc. Stock 12‑Month Price Target Raised to $387.52, Implies 3% Downside
TradingView · 7 d ago
ST
Why Natera (NTRA) Stock Is Up Today
Stock Story · 10 d ago
DP
Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA
dpa-AFX · 10 d ago
RE
FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Reuters · 10 d ago
TR
Natera, Inc. (NTRA) Gets FDA Breakthrough Device Tag for MCED
TradingView · 10 d ago
DO
Natera Price Target Raised to $475.00/Share From $340.00 by Barclays
Dow Jones Newswires · 12 d ago
BU
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
BusinessWire · 12 d ago
TR
Natera, Inc. (NTRA) Starts Randomized Signatera-Guided Melanoma Trial
TradingView · 12 d ago
DO
Natera Price Target Raised to $480.00/Share From $365.00 by Citigroup
Dow Jones Newswires · 13 d ago
TR
Natera, Inc. (NTRA) Reports New Signatera Data Showing High Sensitivity in Multiple Cancers
TradingView · 13 d ago
BU
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
BusinessWire · 13 d ago
RE
Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
Reuters · 14 d ago
BU
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
BusinessWire · 14 d ago
More news →